Dr. Paul Martin, MD
Claim this profileUniversity of Miami
Studies Hepatitis
Studies Non-invasive Indices to Predict Hepatic Fibrosis in BA Patients.
9 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Paul Martin, MD is currently running
INT-787
for Alcoholic Hepatitis
This trial tests a new drug called INT-787 for people with severe liver damage from heavy drinking. It aims to see if the drug is safe and effective, and how the body processes it. The goal is to find out if INT-787 can help improve liver health in these patients. Previous studies have shown that similar treatments can protect against liver injury.
Recruiting0 awards Phase 2
DMR
for Type 2 Diabetes
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled with insulin therapy. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham treatment arm will be offered cross over to receive the DMR treatment at 48 weeks and will be followed per protocol for 48 weeks post treatment.
Recruiting0 awards N/A7 criteria
More about Paul Martin, MD
Clinical Trial Related6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Paul Martin, MD has experience with
- Placebo
- Duodenal Mucosal Resurfacing (DMR)
- Duodenal Mucosal Resurfacing (Sham)
- BIV201
- Albutein 20% Injectable Solution
- EDP-305
Breakdown of trials Paul Martin, MD has run
Hepatitis
Non-invasive Indices to Predict Hepatic Fibrosis in BA Patients.
Cirrhosis
Ascites
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Paul Martin, MD specialize in?
Paul Martin, MD focuses on Hepatitis and Non-invasive Indices to Predict Hepatic Fibrosis in BA Patients.. In particular, much of their work with Hepatitis has involved treating patients, or patients who are undergoing treatment.
Is Paul Martin, MD currently recruiting for clinical trials?
Yes, Paul Martin, MD is currently recruiting for 3 clinical trials in Miami Florida. If you're interested in participating, you should apply.
Are there any treatments that Paul Martin, MD has studied deeply?
Yes, Paul Martin, MD has studied treatments such as Placebo, Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham).
What is the best way to schedule an appointment with Paul Martin, MD?
Apply for one of the trials that Paul Martin, MD is conducting.
What is the office address of Paul Martin, MD?
The office of Paul Martin, MD is located at: University of Miami, Miami, Florida 33137 United States. This is the address for their practice at the University of Miami.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.